Welcome to our dedicated page for Merck & Co. news (Ticker: $MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co.'s position in the market.
Merck provided an update on the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA in combination with chemotherapy for patients with high-risk endometrial cancer. The trial did not meet its primary endpoint of disease-free survival. The safety profile of KEYTRUDA was consistent with previous studies. Merck will continue to expand the role of KEYTRUDA in endometrial cancer treatment.
Merck (NYSE:MRK) has exceeded its goal of reaching 25 million women by 2025 through its global maternal health initiative, Merck for Mothers, now reaching over 30 million women worldwide. The initiative supports the UN's Sustainable Development Goal 3 by focusing on reducing maternal mortality rates and improving access to health care. Through public-private collaborations in over 70 countries, Merck for Mothers has made significant impacts in countries like India, Brazil, Kenya, Nigeria, and the United States.
Merck, trading as MRK on NYSE, will have its CFO participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 15, 2024. The event will be broadcast live for investors, analysts, and the public.
Merck (MRK) announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The trial showed a statistically significant and clinically meaningful improvement in OS compared to placebo, with encouraging results from the progression-free survival, overall response rate, and duration of response data. Merck continues to study KEYTRUDA in gastrointestinal cancers for multiple uses.
Merck (NYSE: MRK) announced positive results from the Phase 3 STRIDE-10 trial evaluating V116, an adult-specific 21-valent pneumococcal conjugate vaccine. The trial showed noninferior immune responses compared to PPSV23 for common serotypes, superior responses for unique serotypes, and a safety profile comparable to PPSV23. The data support V116 as a potential preventative option for invasive pneumococcal disease in adults.
